IV-275

IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345) . IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide[1].

Product Specifications

UNSPSC

12352005

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iv-275.html

Solubility

10 mM in DMSO

Smiles

COC1=CC=C(N2[C@H]3CN([C@@H](C2)C3)C(OC4=CC(F)=C(C=C4)F)=O)C=C1

Molecular Formula

C19H18F2N2O3

Molecular Weight

360.35

References & Citations

[1]Yang C, et al. Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma. J Cell Mol Med. 2023 Sep;27 (18) :2770-2781.